[A clinical evaluation of CA 125 levels in serum, ascites and pleural effusion].
CA 125 in serum, ascites and pleural effusion has been measured in various diseases by an immunoradiometric assay using ELISA CA 125 Kit for an evaluation of its clinical significance as a possible tumor marker. Serum CA 125 was found to be elevated in 90% of the cases involving ovarian cancer and especially in cases of serous cystadenocarcinoma in the early stages, though these serum levels decreased after effective treatment. The CA 125 also was elevated in 63% of the cases involving lung cancer, mostly in the advanced cases regardless of the histological type. CA 125 in ascites proved to be only elevated in malignant diseases, but it was equally high in pleural effusions both in benign and malignant diseases.
D000951:Antigens, Neoplasm / Q000032:analysis*; D015295:Antigens, Tumor-Associated, Carbohydrate; D001202:Ascitic Fluid / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000032:analysis; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology*; D008297:Male; D010051:Ovarian Neoplasms / Q000276:immunology*; D010996:Pleural Effusion / Q000276:immunology*
D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor